HYUNDAI BIOSCIENCE announced on the 26th that it will present the clinical results of 'Jepti' at the U.S. Rapid Response Partnership Annual Meeting. Jepti is a universal antiviral candidate substance that can treat various respiratory viral diseases.
The Rapid Response Partnership is a program where agencies under the U.S. health authorities gather to present technologies, match projects, and conduct early reviews. It will take place in Washington, D.C., for two days until the 27th. The company explained that it has been invited officially by the U.S. health authorities to present Jepti.
Bae Byeong-jun, president of HYUNDAI BIOSCIENCE, said, "The fact that Jepti has been recognized by the U.S. health authorities is significant," adding, "We will lead pandemic response strategies in collaboration with the international health security system."